Pfizer, BioNTech seek US vaccine clearance for children 5-11
The US Food and Drug Administration has set a date of Oct. 26 for its panel of outside advisers to meet and discuss the application, making it possible for children in this age group - numbering around 28 million - to begin receiving the two-dose Pfizer/BioNTech vaccine shortly afterward. "With new cases in children in the US continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19," Pfizer wrote on Twitter.
The vaccine already has won US emergency use authorization in teens ages 12 to 15 and is fully approved by regulators for people ages 16 and up. The Pfizer/BioNTech vaccine is one of three in use in the United States, along with the two-dose Moderna vaccine and the single-dose Johnson Johnson version, neither of which has won full regulatory approval for any age group.
A rapid authorization of the Pfizer/BioNTech vaccine in young kids could help mitigate a potential surge of cases in the coming weeks and months, with schools open nationwide and colder weather driving activities indoors. If given regulatory authorization, the two-dose Pfizer/BioNTech vaccine would become the first COVID-19 shot made available to children 5 to 11 in the United States.The Pfizer/BioNTech vaccine has been shown to induce a strong immune response in 5 to 11-year-olds in a 2,268-participant clinical trial, the companies said on Sept. 20.
The vaccine could be ready for roll out as early as November pending approval from federal regulatory health agencies, White House COVID-19 response coordinator Jeffrey Zients said on CNN.Once the authorization is granted, Zients said: "We are ready. We have the supply. We're working with states to set up convenient locations for parents and kids to get vaccinated including pediatricians' offices and community sites."
